Settled
Do sulfonylureas & glinides improve cardiovascular events versus placebo?
Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, repeated by independent trials.
NoUnsureYes
- Belief
- 0.96 (range 0.81–1.00)
- Trials for
- 2
- Trials against
- 0
- Inconclusive
- 0
Already under way
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · active not recruiting · started 2021
The evidence so far
- Registered trials
- 17
- With posted results
- 6
- Published papers
- 11
Of 3 decided analyses: 2 favor sulfonylureas & glinides, 1 find no difference, 0 favor the comparator.
Papers
- Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.Trial report · 2013
- Comparative effect of saxagliptin and glimepiride with a composite endpoint of adequate glycaemic control without hypoglycaemia and without weight gain in patients uncontrolled with metformin therapy: Results from the SPECIFY study, a 48-week, multi-centre, randomized, controlled trial.Trial report · 2019
- The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.Meta-analysis / systematic review · 2014
- Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.Meta-analysis / systematic review · 2022
- Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.Meta-analysis / systematic review · 2017
- Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.Meta-analysis / systematic review · 2016
Trials
- Effects of a Pioglitazone/Metformin Fixed Combination in Comparison to Metformin in Combination With Glimepiride on Diabetic DyslipidemiaNCT00770653 · 1 posted result
- The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery DiseasesNCT03693560
- A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and GlycaemiaNCT00379769 · 10 posted results
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted LearningNCT05073692 · 1 posted result
- BESTMED: Observational Evaluation of Second Line Therapy Medications in DiabetesNCT05161429
- Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational StudyNCT02456428
- A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and GlimepirideNCT01075282 · 1 posted result
- A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)NCT01769378 · 1 posted result